Drugs / Y-3
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07692685 | May → Jun 2026 | — | Neurodawn Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07055412 | Jul → Oct 2025 overdue | — | Neurodawn Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07068841 | May → Jun 2025 | — | Neurodawn Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06770491 | Feb → Sep 2025 | — | Neurodawn Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT06374667 Comparator | Apr 2024 → Mar 2026 overdue | ischemic stroke | yilong Wang | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Y-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07055412 ↗ |
| Known as | Y-3 for Injection | “From Day 5 to Day 14, 40 mg of Y-3 for Injection shall be administered via intravenous infusion once daily in the morning for 10 consecutive days” NCT07692685 ↗ |
| Route | Intravenous | “Y-3 intravenous injection” NCT06374667 ↗ |